Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Diseases of the Colon & Rectum
Published in: Diseases of the Colon & Rectum 3/2007

01-03-2007

Evidence of Clinical Activity for Cetuximab Combined with Irinotecan in a Patient with Refractory Anal Canal Squamous-Cell Carcinoma: Report of a Case

Authors: Lan K. Phan, M.P.A.S., P.A.-C., Paulo M. Hoff, M.D., F.A.C.P.

Published in: Diseases of the Colon & Rectum | Issue 3/2007

Login to get access

Abstract

Because of the high cure rate of localized anal cancers from combined modality treatment, there is little that is known for the treatment of patients who progress to have metastatic disease. Treatments currently used are based on activity demonstrated in other cancers with similar histology. Cetuximab, a molecular-targeted therapy, is an antibody directed against epidermal growth factor receptor that has demonstrated anticancer activity in several cancers. We report a female patient with refractory anal cancer who achieved an excellent response to the combination of cetuximab and irinotecan after having failed single-agent irinotecan.
Literature
1.
Jemal, A, Murray, T, Ward, E,  et al. 2005Cancer statistics, 2005CA Cancer J Clin551030PubMedCrossRef
2.
3.
Cummings, BJ 1996Anal canal cancer: current treatment and resultsAnn Acad Med Singapore25460467PubMed
4.
Nigro, ND, Seydel, HG, Considine, B,  et al. 1983Combined preoperative radiation and chemotherapy for squamous-cell carcinoma of the anal canalCancer5118261829PubMedCrossRef
5.
Herbst, RS, Onn, A, Mendelsohn, J 2003The role of growth factor signaling in malignancyCancer Treat Res1151972PubMedCrossRef
6.
Kabbinavar, F, Hurwitz, HI, Fehrenbacher, L,  et al. 2003Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancerJ Clin Oncol216065PubMedCrossRef
7.
Kim, ES, Vokes, EE, Kies, MS 2004Cetuximab in cancers of the lung and head & neckSemin Oncol316167PubMedCrossRef
8.
Cunningham, D, Humblet, Y, Siena, S,  et al. 2004Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancerN Engl J Med351337345PubMedCrossRef
9.
Bancroft, CC, Chen, Z, Yeh, J,  et al. 2002Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-kappaB and AP-1 activation and IL-8 and VEGF expression in human head and neck Squamous-cell carcinoma linesInt J Cancer99538548PubMedCrossRef
10.
Busse, D, Yakes, FM, Lenferink, AE,  et al. 2001Tyrosine kinase inhibitors: rationale, mechanisms of action, and implications for drug resistanceSemin Oncol284755PubMedCrossRef
11.
Arteaga, CL 2001The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasiaJ Clin Oncol1932S40SPubMed
Metadata
Title
Evidence of Clinical Activity for Cetuximab Combined with Irinotecan in a Patient with Refractory Anal Canal Squamous-Cell Carcinoma: Report of a Case
Authors
Lan K. Phan, M.P.A.S., P.A.-C.
Paulo M. Hoff, M.D., F.A.C.P.
Publication date
01-03-2007
Publisher
Springer-Verlag
Published in
Diseases of the Colon & Rectum / Issue 3/2007
Print ISSN: 0012-3706
Electronic ISSN: 1530-0358
DOI
https://doi.org/10.1007/s10350-006-0786-9

Other articles of this Issue 3/2007

Diseases of the Colon & Rectum 3/2007 Go to the issue

OriginalPaper

Clinical Characteristics and Outcomes in Patients with Advanced Rectal Cancer: A National Prospective Cohort Study

OriginalPaper

Routine Mobilization of the Splenic Flexure is not Necessary During Anterior Resection for Rectal Cancer

OriginalPaper

Bacterial Translocation May Influence the Long-Term Survival in Colorectal Cancer Patients

Technical Note

Assistance of Colorectal Stent Insertion by Sphincterotome

OriginalPaper

The Advantages of Volume Rendering in Three-Dimensional Endosonography of the Anorectum

Current Status

Serotonin and Its Role in Colonic Function and in Gastrointestinal Disorders